Kyntra Bio (KYNB) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 30, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, latest quarter: NoneNo large changes
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about KYNB filings

Are insiders buying or selling Kyntra Bio, Inc. (KYNB) stock?

Neither. Kyntra Bio, Inc. (KYNB) insiders filed no open-market purchases or sales in the 90 days to Oct 30, 2026, according to SEC Form 4 filings.

Which members of Congress have traded KYNB recently?

None. No member of Congress disclosed a KYNB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this KYNB smart-money data?

This summary uses filings available on Oct 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

TWWettigInsider, filed May 18Bought$19.9K

Smart money on KYNB

Lean long1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Thane Wettig, bought $19.9K, open market, filed May 18
Lean long · thin1 buy · $19.9K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
No recent fund filings found
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about KYNB filings

Are insiders buying or selling Kyntra Bio, Inc. (KYNB) stock?

Neither. Kyntra Bio, Inc. (KYNB) insiders filed no open-market purchases or sales in the 90 days to Oct 30, 2026, according to SEC Form 4 filings.

Which members of Congress have traded KYNB recently?

None. No member of Congress disclosed a KYNB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this KYNB smart-money data?

Insiders

What insiders are doing

1 trade · 6 mo

Bought$20K

Buys (1)

WT
Wettig Thane
CEO · May 18
$20K
bought

Other smart money signals

Activist stakes, short interest & more

1 item

SI
Short Interest ChangeLight
short-volume tape softening: latest 27.7% fell 6.3pp vs 19d avg 34.0%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 10, 2026

Earnings came in 47.2% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 10, 2026

Period ending

Jun 30, 2026

Earnings per share

-$4.68-47.17% miss

-$3.18 expected

Revenue

-$1.5M

SEC filing

Next report

Estimated report: Nov 9, 2026, in 10 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 10, 2026	-$4.68 / -$3.18Alpha Vantage	-47.17% miss	-$1.5M No estimateSEC filing	Unavailable
Mar 31, 2026	May 11, 2026	-$3.76 / -$3.35Alpha Vantage	-12.24% miss	$3.7M No estimateSEC filing	Unavailable
Dec 31, 2025	Mar 16, 2026	-$3.51 / -$3.88Alpha Vantage	+9.65% beat	$1.3M No estimate	Unavailable
Sep 30, 2025	Nov 10, 2025	$49.61 / -$4.00Alpha Vantage	+$53.61 beat	$1.1M No estimateSEC filing	Unavailable
Jun 30, 2025	Aug 11, 2025	-$1.88 / $1.00Alpha Vantage	-$2.88 miss	$1.3M No estimateSEC filing	Unavailable
Mar 31, 2025	May 12, 2025	$1.25 / $0.50Alpha Vantage	+150.00% beat	$2.7M No estimateSEC filing	Unavailable
Dec 31, 2024	Mar 17, 2025	$0.18 / -$0.17Alpha Vantage	+$0.35 beat	-$123.3M No estimate	Unavailable
Sep 30, 2024	Nov 12, 2024	$0.37 / -$9.50Alpha Vantage	+103.89% beat	$123.0K No estimateSEC filing	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $4.80
52-wk high: $11.39
High: $4.85
52-wk low: $4.32
Low: $4.50
Prev close: $4.72
Mkt cap: $19.1M
ROE: +0.0%
Fwd P/E: 61.4x
Beta: 1.05
P/S: 4.1x
P/B: 80.4x
Profit margin: +3969.0%
Op margin: +1192.0%

Jun 2025 to Mar 2026

What it sold, what it cost, what was left.

RevenueProfit

Jun 2025Sep 2025Dec 2025Mar 2026

Income statement, 4 periods, all values in US dollars
USD	Jun 2025	Sep 2025	Dec 2025	Mar 2026
What came in
RevenueTotal revenue	$1.3M	$1.1M	$1.3M	$3.7M
Cost of what it soldCost of revenue	$306.0K	$134.0K	-$463.0K	$4.1M
Gross profit	$1.0M	$942.0K	$1.7M	-$368.0K
What it spent
Research and development	$5.9M	$1.2M	$7.3M	$7.6M
Sales and adminSelling, general and administrative	$7.1M	$5.3M	$7.3M	$5.9M
Other operating costsOperating costs not itemised in the filing's summary	-$221.0K	-$192.0K	$1.3M	—
Total operating expenses	$12.7M	$6.3M	$15.8M	$13.4M
What was left
Operating profitOperating income	-$11.7M	-$5.4M	-$14.1M	-$13.8M
Interest on debtInterest expense	$2.0M	$2.1M	$2.4M	$2.4M
Profit before tax	-$13.8M	-$13.1M	-$14.6M	-$15.1M
TaxIncome tax expense	-$92.0K	—	-$389.0K	$66.0K
Net profitNet income	-$7.6M	$148.5M	$37.9M	-$15.2M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$11.5M	-$10.9M	-$20.9M	-$12.7M

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

24oversold

20D volatility

75%annualized

52-week range

$4.65

$4.32$11.39

20D support

$4.32recent floor

20D resistance

$6.63recent ceiling

Returns

5D -10.9%20D -28.5%60D -33.5%

Price vs moving averages

SMA20 -14.1%SMA50 -31.0%SMA200 -34.8%

Volume pace

0.98xvs prior 20D

Period ending

Reported

EPS / estimate

EPS surprise

Revenue / income

Surprise

Jun 30, 2026

Aug 10, 2026

-$4.68 / -$3.18Alpha Vantage

-47.17% miss

-$1.5M No estimateSEC filing

Unavailable

Mar 31, 2026

May 11, 2026

-$3.76 / -$3.35Alpha Vantage

-12.24% miss

$3.7M No estimateSEC filing

Unavailable

Dec 31, 2025

Mar 16, 2026

-$3.51 / -$3.88Alpha Vantage

+9.65% beat

$1.3M No estimate

Unavailable

Sep 30, 2025

Nov 10, 2025

$49.61 / -$4.00Alpha Vantage

+$53.61 beat

$1.1M No estimateSEC filing

Unavailable

Jun 30, 2025

Aug 11, 2025

-$1.88 / $1.00Alpha Vantage

-$2.88 miss

$1.3M No estimateSEC filing

Unavailable

Mar 31, 2025

May 12, 2025

$1.25 / $0.50Alpha Vantage

+150.00% beat

$2.7M No estimateSEC filing

Unavailable

Dec 31, 2024

Mar 17, 2025

$0.18 / -$0.17Alpha Vantage

+$0.35 beat

-$123.3M No estimate

Unavailable

Sep 30, 2024

Nov 12, 2024

$0.37 / -$9.50Alpha Vantage

+103.89% beat

$123.0K No estimateSEC filing

Unavailable

Income statement, 4 periods, all values in US dollars
USD	Jun 2025	Sep 2025	Dec 2025	Mar 2026
What came in
RevenueTotal revenue	$1.3M	$1.1M	$1.3M	$3.7M
Cost of what it soldCost of revenue	$306.0K	$134.0K	-$463.0K	$4.1M
Gross profit	$1.0M	$942.0K	$1.7M	-$368.0K
What it spent
Research and development	$5.9M	$1.2M	$7.3M	$7.6M
Sales and adminSelling, general and administrative	$7.1M	$5.3M	$7.3M	$5.9M
Other operating costsOperating costs not itemised in the filing's summary	-$221.0K	-$192.0K	$1.3M	—
Total operating expenses	$12.7M	$6.3M	$15.8M	$13.4M
What was left
Operating profitOperating income	-$11.7M	-$5.4M	-$14.1M	-$13.8M
Interest on debtInterest expense	$2.0M	$2.1M	$2.4M	$2.4M
Profit before tax	-$13.8M	-$13.1M	-$14.6M	-$15.1M
TaxIncome tax expense	-$92.0K	—	-$389.0K	$66.0K
Net profitNet income	-$7.6M	$148.5M	$37.9M	-$15.2M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$11.5M	-$10.9M	-$20.9M	-$12.7M

USD

Jun 2025

Sep 2025

Dec 2025

Mar 2026

What came in

RevenueTotal revenue

$1.3M

$1.1M

$1.3M

$3.7M

Cost of what it soldCost of revenue

$306.0K

$134.0K

-$463.0K

$4.1M

Gross profit

$1.0M

$942.0K

$1.7M

-$368.0K

What it spent

Research and development

$5.9M

$1.2M

$7.3M

$7.6M

Sales and adminSelling, general and administrative

$7.1M

$5.3M

$7.3M

$5.9M

Other operating costsOperating costs not itemised in the filing's summary

-$221.0K

-$192.0K

$1.3M

—

Total operating expenses

$12.7M

$6.3M

$15.8M

$13.4M

What was left

Operating profitOperating income

-$11.7M

-$5.4M

-$14.1M

-$13.8M

Interest on debtInterest expense

$2.0M

$2.1M

$2.4M

Profit before tax

-$13.8M

-$13.1M

-$14.6M

-$15.1M

TaxIncome tax expense

-$92.0K

—

-$389.0K

$66.0K

Net profitNet income

-$7.6M

$148.5M

$37.9M

-$15.2M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$11.5M

-$10.9M

-$20.9M

-$12.7M

Kyntra Bio, Inc.

Smart money at a glance

What do analysts expect?

Questions about KYNB filings

Smart money on KYNB

Questions about KYNB filings

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 47.2% below what analysts expected.

Estimated report: Nov 9, 2026, in 10 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Kyntra Bio, Inc.

Smart money at a glance

What do analysts expect?

Questions about KYNB filings

Smart money on KYNB

Questions about KYNB filings

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 47.2% below what analysts expected.

Estimated report: Nov 9, 2026, in 10 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Kyntra Bio, Inc.

Overview

Questions about KYNB filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Ask it in Claude or ChatGPT.

Kyntra Bio, Inc.

Overview

Questions about KYNB filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Ask it in Claude or ChatGPT.